Enfortumab vedotin plus pembrolizumab in cisplatin‐eligible muscle‐invasive bladder cancer: efficacy proven, duration unclear
Massimiliano Depalma,
Francesco Rossi,
Matteo Ferro,
Laura Bukavina,
Giuseppe Di Lorenzo,
Riccardo Autorino BJU International
· Wiley
· 2026-10-21
· DOI: 10.1111/bju.70507
Massimiliano Depalma, Francesco Rossi, Matteo Ferro, Laura Bukavina, Giuseppe Di Lorenzo, Riccardo Autorino. Enfortumab vedotin plus pembrolizumab in cisplatin‐eligible muscle‐invasive bladder cancer: efficacy proven, duration unclear. // BJU International. – 2026. – DOI: 10.1111/bju.70507. – URL: https://bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bju.70507?af=R
Massimiliano Depalma, Francesco Rossi, Matteo Ferro, Laura Bukavina, Giuseppe Di Lorenzo, & Riccardo Autorino (2026). Enfortumab vedotin plus pembrolizumab in cisplatin‐eligible muscle‐invasive bladder cancer: efficacy proven, duration unclear. BJU International. https://doi.org/10.1111/bju.70507
Massimiliano Depalma, et al. “Enfortumab vedotin plus pembrolizumab in cisplatin‐eligible muscle‐invasive bladder cancer: efficacy proven, duration unclear.” BJU International, 2026. doi:10.1111/bju.70507.
@article{Depalma2026,
title = {Enfortumab vedotin plus pembrolizumab in cisplatin‐eligible muscle‐invasive bladder cancer: efficacy proven, duration unclear},
author = {Depalma, Massimiliano and Rossi, Francesco and Ferro, Matteo and Bukavina, Laura and Lorenzo, Giuseppe Di and Autorino, Riccardo},
journal = {BJU International},
year = {2026},
doi = {10.1111/bju.70507},
url = {https://bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bju.70507?af=R}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...